Dave Allen - Articles and news items

GlaxoSmithKline logo

GSK and Theravance announce initiation of phase III programme with fixed dose triple combination treatment FF/UMEC/VI in patients with COPD

Industry news / 16 July 2014 / GlaxoSmithKline

GlaxoSmithKline plc and Theravance, Inc. announced the start of a global phase III study, known as IMPACT, to evaluate the efficacy and safety of the ‘closed’ triple combination of FF/UMEC/VI in patients with chronic obstructive pulmonary disease…

GlaxoSmithKline logo

GSK announces positive results from phase III studies for mepolizumab in severe eosinophilic asthma

Industry news / 12 March 2014 / GlaxoSmithKline

GlaxoSmithKline plc announced that a pivotal phase III study of mepolizumab, an investigational IL-5 antagonist monoclonal antibody, met its primary endpoint of reduction in the frequency of exacerbations…

 

The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...
+